Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES IN	N BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bernard Thierry</u>				2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [TTOO]									neck all	tionship of Reporting Per all applicable) Director			son(s) to Issuer 10% Owner		
(Last)	(Fi	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/25/2021									officer elow)	(give title		Other (specify below)		
(Street) LEXING (City)		tate)	02421 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						Lin	e) X F F P	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			2. Transa Date (Month/Da	Execution Date,				tr. 3, 4 an	4 and Securitie Beneficia Owned F Reported		es Form ally (D) o following (I) (Ir		n: Direct r Indirect sstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
									Code	٧	Amount	(A) or (D)	Price		ınsacti str. 3 a				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date, if any (Month/Day/Year)				Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				C	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock Units	(1)	06/25/2021			A		73,224		(2)		(2)	Common Stock	73,224	\$0.	00	73,22	4	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- 2. The restricted stock units vest in one installment on the earlier of (i) June 25, 2022 and (ii) the date of the next annual meeting of stockholders.

Remarks:

/s/ John Sprague, Attorney-infact

** Signature of Reporting Person

Date

06/29/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.